TY - JOUR
T1 - Seventy-two pulmonary retransplantations for obliterative bronchiolitis
T2 - Predictors of survival
AU - Novick, Richard J.
AU - Schäfers, Hans Joachim
AU - Stitt, Larry
AU - Andréassian, Bernard
AU - Klepetko, Walter
AU - Hardesty, Robert L.
AU - Frost, Adaani
AU - Patterson, G. Alexander
N1 - Funding Information:
We thank the contributing thoracic surgeons, pulmonary medicine physicians, and recipient coordinators who have participated in the pulmonary retransplant registry. We also acknowledge the assistance of Heather Motloch in manuscript preparation and of Theresa Novick, MSc, in data collection and analysis. This study was supported by a block-term grant from the Ontario (Canadian) Thoracic Society.
PY - 1995/7
Y1 - 1995/7
N2 - Background.: Obliterative bronchiolitis (OB) occurs in up to 40% of patients in the intermediate term after lung transplantation. In recent years an increasing number of recipients with end-stage OB have been treated with retransplantation. Methods.: Seventy-two patients with OB underwent retransplantation at 26 North American and European centers a median of 590 days after their first transplant operation. The predictors of survival were determined using life table and Cox proportional hazards methods, and the recurrence rate of OB was determined in survivors. Results.: The actuarial survival rate was 71% ± 5% at 1 month, 43% ± 6% at 1 year, and 35% ± 6% at 2 years; nonetheless, of the 90-day postoperative survivors, 63% ± 7% were alive 2 years after retransplantation. Institutional experience with more than three pulmonary retransplantations (p = 0.008), reoperation in Europe (p = 0.013), donor-recipient ABO blood group identity (p = 0.018), and more recent year of retransplantation (p = 0.03) were associated with survival. On multivariate analysis, reoperation after 1989 (p < 0.001), retransplantation performed in Europe (p = 0.017), and being ambulatory immediately before reoperation (p = 0.022) were found to be predictive of a positive outcome. Pulmonary function test analyses confirmed that the forced expiratory volume in 1 second decreased from postoperative baseline values by 11% ± 9% at 1 year and 27% ± 10% at 2 years (p = 0.02; year 2 versus baseline). Fourteen percent of patients were in stage 3 of the bronchiolitis obliterans syndrome at 1 year postoperatively, with 33% affected at 2 years. Conclusions.: The results of pulmonary retransplantation for OB are improving. Current evidence indicates that OB does not recur in an accelerated manner after retransplantation, although pulmonary function does worsen again by 2 years. Pulmonary retransplantation is appropriate only in selected patients with OB who are ambulatory and are operated on at experienced centers.
AB - Background.: Obliterative bronchiolitis (OB) occurs in up to 40% of patients in the intermediate term after lung transplantation. In recent years an increasing number of recipients with end-stage OB have been treated with retransplantation. Methods.: Seventy-two patients with OB underwent retransplantation at 26 North American and European centers a median of 590 days after their first transplant operation. The predictors of survival were determined using life table and Cox proportional hazards methods, and the recurrence rate of OB was determined in survivors. Results.: The actuarial survival rate was 71% ± 5% at 1 month, 43% ± 6% at 1 year, and 35% ± 6% at 2 years; nonetheless, of the 90-day postoperative survivors, 63% ± 7% were alive 2 years after retransplantation. Institutional experience with more than three pulmonary retransplantations (p = 0.008), reoperation in Europe (p = 0.013), donor-recipient ABO blood group identity (p = 0.018), and more recent year of retransplantation (p = 0.03) were associated with survival. On multivariate analysis, reoperation after 1989 (p < 0.001), retransplantation performed in Europe (p = 0.017), and being ambulatory immediately before reoperation (p = 0.022) were found to be predictive of a positive outcome. Pulmonary function test analyses confirmed that the forced expiratory volume in 1 second decreased from postoperative baseline values by 11% ± 9% at 1 year and 27% ± 10% at 2 years (p = 0.02; year 2 versus baseline). Fourteen percent of patients were in stage 3 of the bronchiolitis obliterans syndrome at 1 year postoperatively, with 33% affected at 2 years. Conclusions.: The results of pulmonary retransplantation for OB are improving. Current evidence indicates that OB does not recur in an accelerated manner after retransplantation, although pulmonary function does worsen again by 2 years. Pulmonary retransplantation is appropriate only in selected patients with OB who are ambulatory and are operated on at experienced centers.
UR - http://www.scopus.com/inward/record.url?scp=0029077332&partnerID=8YFLogxK
U2 - 10.1016/S0003-4975(95)00369-X
DO - 10.1016/S0003-4975(95)00369-X
M3 - Article
C2 - 7598570
AN - SCOPUS:0029077332
SN - 0003-4975
VL - 60
SP - 111
EP - 116
JO - The Annals of thoracic surgery
JF - The Annals of thoracic surgery
IS - 1
ER -